CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the presentation of new preclinical data on AP26113, its investigational dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR), demonstrating that its novel profile allows targeted inhibition of these two clinically validated oncogenic kinases in non-small cell lung cancer (NSCLC). These data are being presented at the International Association for the Study of Lung Cancer (IASLC) 14th World Conference on Lung Cancer being held in Amsterdam, The Netherlands.
